None of the 5 meningiomas harboring SMARCB1 mutation recurred, which is in keeping with the limited published outcome data available in prior studies.4 Only a single tumor harbored a TERT promoter mutation, consistent with the frequency previously reported in atypical meningiomas.44 These findings suggest that CNVs are stronger predictors of RFS than underlying genomic driver mutations. This evidence concerns the gene SMARCB1 and meningioma.